24th Oct 2024 09:22
GSK PLC - London-based pharmaceutical and biotechnology - Tests of Arexvy, GSK's vaccine against respiratory syncytial virus, shows it can protect a wider range of adults. The vaccine already is approved for use in adults aged 60 years and above in more than 50 countries and in adults 50 to 59 in the US and some European countries. New phase IIb and IIIb trials on adults aged 18 to 49 years at risk of RSV show that two doses of Arexvy bring an immune response for adults aged 18 and above that is similar to one dose in adults aged 50 or more, with an acceptable safety profile. Read More
